We retrospectively analyzed 74 patients with Stage IIIB–IV non‐squamous NSCLC, PD‐L1 ≥ 50%, and no EGFR/ALK/ROS1 mutations, treated at a tertiary center in Taiwan (2017–2023). This evidence concerns the gene ROS1 and non-small cell lung carcinoma.